Member Info for sharehunter3

had thought next week with so much news due might have seen a nice move up with share price ,with the testing shortage and ,sadly the increasing covid numbers ,also the disappointing vaccine news
so many buyers taking up shares already this morning ,will the usual N Tto buy that ofen seen when mms run low on shares soon be seen today ,thanks to some sells it currently looking like people are able to buy with out getting quoted N T to buy

my thinking this is still a strong share ,and thinking and hoping only temporary ,and hoping that covid vaccine will continue ,
can only watch and wait for more news ,still interest in covid shares some nice buys going into ncyt this morning

BUYS flowing in nicely now, looking like a strong day ,will look in later

8000 share buy at 3,10 , looking like a strong afternoon might be seen ,

did not expect to read this news ,with how ncyt looking currently , if a good rise is seen there ,and if a dip here ,my plan will be to buy as many azn as can , if a lower share

heading for blue finish ,looking slightly stronger

share price moving up some,maybe move up starting ,had thought next week might see move up starting ,after share price starting off flat today ,

hoping stronger afternoon ,ncyt starting to move ,so hoping odx might also move up more this afternoon and other covid shares

covid shares price movement difficult to work out
Todays post and twitter links , as with many good posts from bladesharp

show how much news due to this share
how much of a rerate with share price due
while find it baffling to see this share price still at this level with the £millions ncyt have coming in from manufacturing
and global sales ,even with the media attention on testing and rising covid number in UK and so many countries ,patient
can some times pay ,

so many covid shares not moving ,yet so much media attention on testing
avct in red today , sng after rns ,now share price dropping back wit sellers ,ncyt even after bladesharps post on 13 area managers not moving , with the news that people watching for at avct ,had been hoping a move up seen ,shares some times can test patience ,some times patience can pay seems to be little movement today across covid shares

all the covid shares not moving today ,even with so much media attention on covid , great move here yesterday ,with really good volume , today looking at covid shares ,find share price movements baffling ,had hoped for a good move up here today ,now stopped watching sng for today ,even after their good rns ,so much selling ,ncyt even after post by bladesharpe this morning on the 13 area managers no movement , with so much volume here yesterday ,and yet today so little movement ,to me difficult to work out ,

if goes into red today ,personly will stop looking for a while ,covid share generally their share price baffling in my view
looked at ncyt ,which many other posters here hold and post at ,stopped looking today after seeing bladesharps post on number of new managers and still no rise ,and to see the selling here today ,as well as the covid , when knowing people and how their life impacted by copd ,might be my last post here today ,will look at some of my other shares ,patience can sometimes pay

personly think a good rns
like the different parts of rns

· Virology

A range of common respiratory viruses including rhinovirus, influenza, adenovirus, respiratory syncytial virus (RSV), human metapneumovirus (HMPV), parainfluenza and coronavirus (the four strains that cause common cold symptoms, but not SARS-CoV-2, the virus that causes COVID-19) were identified in nasopharyngeal and/or sputum samples from the COPD patients in this trial. This is relevant because COVID-19 patients can be coinfected with other respiratory viruses such as influenza. SNG001 has demonstrated antiviral activity against multiple viruses in cell-based assays. Further virology work is being conducted.



Next steps for COPD

COPD exacerbations are the second most common cause of unplanned hospital admission in England,1 and occur most frequently in the winter virus season. The data from this trial, coupled with the data from the COVID-19 trial in hospitalised patients, provide a strong rationale for assessing SNG001 in COPD patients admitted to hospital with exacerbations from confirmed viral lung infections.



Next Steps for COVID-19

Synairgen is in discussions with a number of regulatory agencies worldwide to establish the regulatory route to the approval of SNG001 as a treatment for COVID-19. We are also working closely with the Company's manufacturing partners on scale-up activity and will provide a further update on these matters in due course.

some look to have no patience with shares and sell so quickly ,often think do some actually read the rns , some times need to read a rns twice myself ,each person makes their own decisions

if i happy with a rns , and see sellers leaving ,personly reread the rns ,and if happy make my own investing decisions

from todays rns

· Virology

A range of common respiratory viruses including rhinovirus, influenza, adenovirus, respiratory syncytial virus (RSV), human metapneumovirus (HMPV), parainfluenza and coronavirus (the four strains that cause common cold symptoms, but not SARS-CoV-2, the virus that causes COVID-19) were identified in nasopharyngeal and/or sputum samples from the COPD patients in this trial. This is relevant because COVID-19 patients can be coinfected with other respiratory viruses such as influenza. SNG001 has demonstrated antiviral activity against multiple viruses in cell-based assays. Further virology work is being conducted.



Next steps for COPD

COPD exacerbations are the second most common cause of unplanned hospital admission in England,1 and occur most frequently in the winter virus season. The data from this trial, coupled with the data from the COVID-19 trial in hospitalised patients, provide a strong rationale for assessing SNG001 in COPD patients admitted to hospital with exacerbations from confirmed viral lung infections.



Next Steps for COVID-19

Synairgen is in discussions with a number of regulatory agencies worldwide to establish the regulatory route to the approval of SNG001 as a treatment for COVID-19. We are also working closely with the Company's manufacturing partners on scale-up activity and will provide a further update on these matters in due course.

when they cleared ,will more of a move up be seen

might be day traders selling ,when they cleared hopefully might move up more

nice volume today ,shows how much interest still in covid shares ,also like tweet posted on ncyt share board

NHS area manager , why do ncyt need to employ , NHS area manager ,

shows the interest in covid shares with the right rns to watch the volume of buys going into odx , when one watches that interest and buying ,in my view cancels out the view of some posters that interest in covid shares decreasing